A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: A gynecologic oncology group study

Gynecologic Oncology

Volumn 118, Issue 2, 2010, Pages 139-144

  Miller, Brigitte E ^a   Blessing, John A ^b   Stehman, Frederick B ^c   Shahin, Mark S ^d   Yamada, S Diane ^e   Secord, Angeles Alvarez ^f   Warshal, David P ^g   Abulafia, Ovadia ^h   Richards, William E ⁱ   Van Le, Linda ^j  

^a CAROLINAS MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d ABINGTON MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g Department of Anesthesiology   (United States)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CINCINNATI   (United States)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

Carcinosarcoma; Docetaxel; Gemcitabine

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DIURETIC AGENT; DOCETAXEL; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SCREENING; DRUG WITHDRAWAL; GYNECOLOGY; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; ONCOLOGY; OVERALL SURVIVAL; PAIN; PATHOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THERAPY DELAY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CARCINOSARCOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOSARCOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TAXOIDS; UTERINE NEOPLASMS;

EID: 77954244464     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.024     Document Type: Article

References (54)

1. H.D. Homesley, V.L. Filiaci, M. Markman, P. Bitterman, L. Eaton, and L. Kilgore Phase III trial of ifosfamide with or without paclitaxel in advanced uterine sarcoma: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 526 531
2. M.A. Powell, V.L. Filiaci, P.G. Rose, R.S. Mannel, P. Hanjani, and K. DeGeest A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group (GOG) study J Clin Oncol 27 ASCO#5515 2009 280s [Abstract]
3. G.A. Omura, F.J. Major, J.A. Blessing, T.V. Sedlacek, J.T. Thigpen, and W.T. Creasman A randomized study of adriamycin with and without dimethyl triazenimidazole carboxamide in advanced uterine sarcomas Cancer 52 1983 626 632
4. J.T. Thigpen, J.A. Blessing, and G.D. Wilbanks Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus: a phase II trial of the Gynecologic Oncology Group Am J Clin Oncol 9 1986 18 20
5. G.P. Sutton, J.A. Blessing, H.D. Homesley, and J.H. Malfetano A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study Gynecol Oncol 53 1994 24 26
6. J.P. Curtin, J.A. Blessing, J.T. Soper, and K. DeGeest Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study Gynecol Oncol 83 2001 268 270
7. G. Sutton, V.L. Brunetto, L. Kilgore, J.T. Soper, J. Bell, and R. McGehee A phase III trial of ifosfamide with or without cisplatin in carcinoma of the uterus: a Gynecologic Oncology Group study Gynecol Oncol 79 2000 147 153
8. A.R. Günthert, S. Pilz, W. Kuhn, G. Emons, and H. Meden Docetaxel is effective in the treatment of metastatic endometrial cancer Anticancer Res 19 1999 3459 3461
9. S. Lincoln, J.A. Blessing, R.B. Lee, and T.F. Rocereto Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 88 2003 277 281
10. Q.G. van Hoesel, J. Verweij, G. Catimel, M. Clavel, P. Kerbrat, and A.T. van Oosterom Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group Ann Oncol. 5 1994 539 542
11. S.R. Patel, V. Gandhi, J. Jenkins, N. Papadopolous, M.A. Burgess, and C. Plager Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation J Clin Oncol 19 2001 3483 3489
12. B.W. Robinson, L. Ostruszka, M.M. Im, and D.S. Shewach Promising combination therapies with gemcitabine Semin Oncol 5 2004 2 12
13. K.M. Leu, L.J. Ostruszka, D. Shewach, M. Zalupski, V. Sondak, and J.S. Biermann Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma J Clin Oncol 22 2004 1706 1712
14. M.L. Hensley, R. Maki, E. Venkatraman, G. Geller, M. Lovegren, and C. Aghajanian Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J Clin Oncol 20 2002 2824 2831
15. J.D. Hainsworth, H.A. Burris III, J.B. Erland, M. Thomas, and F.A. Greco Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer J Clin Oncol 16 1998 2164 2168
16. J.D. Hainsworth, H.A. Burris III, and S. Litchy Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial Cancer 89 2000 328 333 (Pubitemid 30489880)
17. H.J. Burstein, J. Manola, J. Younger, L.M. Parker, C.A. Bunnell, and R. Scheib Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 2000 1212 1219
18. M. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Phase 2 trial of single agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol Oncol 90 2003 593 596
19. N. Tsavaris, C. Kosmas, P. Gouveris, K. Gennatas, A. Polyzos, and D. Mouratidou Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer Invest New Drugs 22 2004 193 198
20. K.N. Ganjoo, M.S. Gordon, A.B. Sandler, R.E. Warnr, K. Fife, and S. Poirier A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study Oncology 62 2002 299 304
21. B.P. Schneider, K.N. Ganjoo, D.E. Seitz, J. Picus, F. Fata, and C. Stoner Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study Oncology 65 2003 218 223
22. T. Mekhail, T.E. Hutson, P. Elson, G.T. Budd, G. Srkalovic, and T. Olencki Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies Cancer 97 2003 170 178
23. J.D. Hainsworth, J.B. Erland, J.H. Barton, D.S. Thompson, M.P. Stagg, and J.E. Bradof Combination treatment with weekly docetaxel and gemcitabine for advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network Phase II trial Clin Lung Cancer 5 2003 33 38
24. C. Kouroussis, D. Mavroudis, S. Kakolyris, A. Voloudaki, K. Kalbakis, and J. Souglakos High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose finding study Lung Cancer 44 2004 363 368
25. T.T. Chen, and T. NG Optimal flexible designs in phase II clinical trials Statistics Med 17 1998 2301 2312
26. L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
27. W.G. McCluggage Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 55 2002 321 325
28. F. Amant, V. Vloeberghs, H. Woestenborghs, P. Moerman, and I. Vergote Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma Tumorigenesis Gynecol Oncol 90 2003 372 377
29. F. Amant, I. Cadron, L. Fuso, P. Berteloot, E. de Jonge, and G. Jacomen Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer Gynecol Oncol 98 2005 274 280
30. K. Shen, M.D. Li, Y.J. Feng, D. Ma, Z.T. Li, and X. Xie A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer Zhonghua Yi Xue Za Zhi 85 2005 2099 2103
31. D. Gupta, R.L. Owers, M. Kim, D.Y. Kuo, G.S. Huang, and S. Shahabi A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers Gynecol Oncol 113 2009 327 330
32. R. Sharma, J. Graham, H. Mitchell, A. Brooks, S. Blagden, and H. Gabra Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer Br J Cancer 100 2009 707 712
33. G.P. Sutton, J.A. Blessing, H.D. Homesley, W.P. McGuire, and L. Adcock Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study Cancer 73 1994 1453 1455
34. A.T. van Oosterom, H.T. Mouridsen, O.S. Nielsen, P. Dombernowsky, K. Krzemieniecki, and I. Judson Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients Eur J Cancer 38 2002 2397 2406
35. H.B. Muss, B. Bundy, P.J. DiSaia, H.D. Homesley, W.C. Fowler Jr., and W. Creasman Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group) Cancer 55 1985 1648 1653
36. J.T. Thigpen, J.A. Blessing, L.D. Lagasse, P.J. DiSaia, and H.D. Homesley Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study Am J Clin Oncol 7 1984 253 256
37. D.S. Miller, J.A. Blessing, S.S. Lentz, and S.E. Waggoner A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study Gynecol Oncol 87 2002 247 251
38. D.S. Miller, J.A. Blessing, J. Schilder, A. Munkarah, and Y.C. Lee Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study Gynecol Oncol 98 2005 217 221
39. D.G. Gallup, J.A. Blessing, W. Andersen, M.A. Morgan Gynecologic Oncology Group Study Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a Gynecologic Oncology Group study Gynecol Oncol 89 2003 48 51
40. A.A. Garcia, J.A. Blessing, S. Nolte, R.S. Mannel Gynecologic Oncology Group A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group Gynecol Oncol 111 2008 22 26
41. K.Y. Look, A. Sandler, J.A. Blessing, J.A. Lucci III, P.G. Rose Gynecologic Oncology Group (GOG) Study Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study Gynecol Oncol 92 2004 644 647
42. M.L. Hensley, J.A. Blessing, K. Degeest, O. Abulafia, P.G. Rose, and H.D. Homesley Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Gynecol Oncol 109 2008 323 328
43. J.T. Thigpen, M.F. Brady, H.D. Homesley, J. Malfetano, B. DuBeshter, and R.A. Burger Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study J Clin Oncol 22 2004 3902 3908
44. J.T. Thigpen, J.A. Blessing, H. Homesley, W.T. Creasman, and G. Sutton Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study Gynecol Oncol 33 1989 68 70
45. J.T. Thigpen, J.A. Blessing, J. Beecham, H. Homesley, and E. Yordan Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study J Clin Oncol 9 1991 1962 1966
46. S. Wadler, D.E. Levy, S.T. Lincoln, G.S. Soori, J.C. Schink, and G. Goldberg Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93 J Clin Oncol 21 2003 2110 2114
47. D.S. Miller, J.A. Blessing, L.C. Kilgore, R. Mannel, and L. Van Le Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study Am J Clin Oncol 23 2000 355 357
48. H.G. Ball, J.A. Blessing, S.S. Lentz, and D.G. Mutch A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study Gynecol Oncol 62 1996 278 281
49. G. Sutton, J.A. Blessing, and H. Ball Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study Gynecol Oncol 1999 74346 74349
50. A.R. Günthert, S. Ackermann, M.W. Beckmann, O. Camara, L. Kiesel, and K. Rensing Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4 Gynecol Oncol 104 2007 86 90
51. V. Bramwell, M. Blackstein, K. Belanger, S. Verma, S. Beare, and E. Eisenhauer A phase II study of docetaxel in chemotherapy-naïve patients with recurrent or metastatic adult soft tissue sarcoma Sarcoma 2 1998 29 33
52. B. Sorbe, H. Andersson, K. Boman, P. Rosenberg, and M. Kalling Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up Int J Gynecol Cancer 18 2008 803 808
53. P.J. Hoskins, N. Le, S. Ellard, U. Lee, L.A. Martin, and K.D. Swenerton Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience Gynecol Oncol 108 2008 58 62 (Pubitemid 350299420)
54. M.L. Hensley, J.A. Blessing, R. Mannel, and P.G. Rose Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial Gynecol Oncol 109 2008 329 334